Current Report Filing (8-k)
November 09 2016 - 6:56AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report:
November 9, 2016
(Date of earliest event reported)
LOXO ONCOLOGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-36562
|
|
46-2996673
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
281 Tresser Boulevard, 9
th
Floor
Stamford, CT
|
|
06901
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(203) 653-3880
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On
November 7, 2016, the Board of Directors (the
Board
) of Loxo Oncology, Inc. (
Loxo
) appointed Steven D. Harr as an independent Class I director, with a term that will expire at Loxos annual stockholder meeting in 2018.
As CFO and head of corporate development at Juno Therapeutics, Dr. Harr leads the finance organization and corporate strategy. From May 2010 until joining Juno in April 2014, Dr. Harr was managing director and head of Biotechnology Investment Banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanleys lead biotech research analyst and co-head of Global Healthcare Research. Dr. Harr received a B.A. in economics from College of the Holy Cross in 1993 and an M.D. from The Johns Hopkins University School of Medicine in 1998. Dr. Harr was a resident in internal medicine at the University of California, San Francisco from 1998 to 2000. Dr. Harr is also a member of the board of directors of JW Therapeutics.
Loxo issued a press release announcing Dr. Harrs appointment to the Board on November 9, 2016, a copy of which is attached to this Form 8-K as Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release dated November 9, 2016
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Loxo Oncology, Inc.
|
|
|
|
|
Date: November 9, 2016
|
By:
|
/s/ Joshua H. Bilenker, M.D.
|
|
Name:
|
Joshua H. Bilenker, M.D.
|
|
Title:
|
Chief Executive Officer
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release dated November 9, 2016
|
4
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Apr 2023 to Apr 2024